Gestational diabetes: A link between OGTT, maternal-fetal outcomes and maternal glucose tolerance after childbirth.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
27 11 2020
Historique:
received: 26 04 2020
revised: 03 07 2020
accepted: 02 08 2020
entrez: 26 11 2020
pubmed: 27 11 2020
medline: 15 12 2020
Statut: ppublish

Résumé

The relationship among distribution of pathological values at the Oral Glucose Tolerance Test (OGTT), metabolic risk factors and pregnancy outcomes in women with Gestational Diabetes (GDM), has not been clearly identified. We retrospectively compared metabolic and therapeutic parameters, maternal-fetal outcomes and post-partum OGTTs, with respect to the number and distribution of altered values of diagnostic OGTT in pregnancy. Secondly, we assessed whether insulin therapy predictive factors were identifiable. This analysis included 602 pregnant women with GDM, followed in Diabetes and Pregnancy Unit of Perugia Hospital from diagnosis to childbirth. All women were diagnosed diabetic upon 75g OGTT, according IADPSG criteria. Women were divided into 3 groups, respect to distribution of diagnostic blood glucose (BG) values at OGTT: Group 1: only fasting BG (OGTT0h); Group 2: 1 and/or 2h (OGTT1-2h); Group 3: both fasting and 1 h and/or 2h (OGTT0+1-2h) BG. Pregnant women with fasting hyperglycemia at OGTT (Groups 1 and 3) had similar metabolic characteristics (weight, prevalence of obesity, gestational weight gain, HbA1c), a greater need for insulin therapy, and a higher risk of impaired glucose tolerance persistence after childbirth, as compared to Group 2. No significant differences were observed in terms of maternal and neonatal outcomes (p > 0.05), except for a greater prevalence of caesarean sections in Group 3. The metabolic characteristics of GDM women are mirrored by OGTT values at diagnosis, but are not associated with adverse pregnancy outcomes. Intensive management and a tailored treatment of GDM improve maternal-neonatal outcomes, regardless of diagnostic values distribution and pre-gestational metabolic characteristics.

Sections du résumé

BACKGROUND AND AIM
The relationship among distribution of pathological values at the Oral Glucose Tolerance Test (OGTT), metabolic risk factors and pregnancy outcomes in women with Gestational Diabetes (GDM), has not been clearly identified. We retrospectively compared metabolic and therapeutic parameters, maternal-fetal outcomes and post-partum OGTTs, with respect to the number and distribution of altered values of diagnostic OGTT in pregnancy. Secondly, we assessed whether insulin therapy predictive factors were identifiable.
METHODS AND RESULTS
This analysis included 602 pregnant women with GDM, followed in Diabetes and Pregnancy Unit of Perugia Hospital from diagnosis to childbirth. All women were diagnosed diabetic upon 75g OGTT, according IADPSG criteria. Women were divided into 3 groups, respect to distribution of diagnostic blood glucose (BG) values at OGTT: Group 1: only fasting BG (OGTT0h); Group 2: 1 and/or 2h (OGTT1-2h); Group 3: both fasting and 1 h and/or 2h (OGTT0+1-2h) BG. Pregnant women with fasting hyperglycemia at OGTT (Groups 1 and 3) had similar metabolic characteristics (weight, prevalence of obesity, gestational weight gain, HbA1c), a greater need for insulin therapy, and a higher risk of impaired glucose tolerance persistence after childbirth, as compared to Group 2. No significant differences were observed in terms of maternal and neonatal outcomes (p > 0.05), except for a greater prevalence of caesarean sections in Group 3.
CONCLUSION
The metabolic characteristics of GDM women are mirrored by OGTT values at diagnosis, but are not associated with adverse pregnancy outcomes. Intensive management and a tailored treatment of GDM improve maternal-neonatal outcomes, regardless of diagnostic values distribution and pre-gestational metabolic characteristics.

Identifiants

pubmed: 33239164
pii: S0939-4753(20)30338-0
doi: 10.1016/j.numecd.2020.08.002
pii:
doi:

Substances chimiques

Biomarkers 0
Blood Glucose 0
Glycated Hemoglobin A 0
Insulin 0
hemoglobin A1c protein, human 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2389-2397

Informations de copyright

Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Auteurs

Sara Parrettini (S)

Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy.

Ludovica Ranucci (L)

Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy.

Antonella Caroli (A)

Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy.

Vittorio Bini (V)

Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy.

Riccardo Calafiore (R)

Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy.

Elisabetta Torlone (E)

Department of Medicine, Division of Endocrinology and Metabolism, University of Perugia, Hospitals and Clinics, Piazzale Menghini 1, 06129, Sant'Andrea delle Fratte, Perugia, Italy. Electronic address: elisabetta.torlone@ospedale.perugia.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH